Answers are grounded in this paper and cite their sources.
Extracellular vesicles (EVs) have emerged as groundbreaking natural nanocarriers and potent mediators in tissue regeneration. Their evolutionarily conserved role in intercellular communication, combined with superior biocompatibility and their innate ability to transport functional biomolecules across biological barriers, positions EVs as paradigm-shifting alternatives to synthetic delivery systems for clinical translation. EVs secreted by stem cells stimulate angiogenesis, modulate immune responses, and promote cellular proliferation, thereby aiding in tissue repair and potentially reducing the risks associated with cell-based therapies. However, the biological advantages of EVs cannot be fully realized when used alone. The integration of EVs with biomaterials strengthens their stability, targeting precision, and retention at injury sites. This review highlights the transformative potential of EVs and biological scaffolds, focusing on these applications in tissue regeneration. Despite the promising therapeutic potential of EVs and biological scaffolds, their clinical translation presents several key challenges. These include achieving large-scale production and efficient loading of therapeutic payloads, addressing ethical and regulatory considerations, and navigating the path toward EV engineering and commercialization. By systematically addressing these hurdles, EVs combined with biomaterial scaffolds can bridge the gap between nanomedicine research and clinically viable therapies, ultimately redefining the prospects of regenerative medicine.
No takes yet. Share an insight, caveat, or question.
Kausar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: